MCA logo



Treatment of HER2+ Breast Cancer: Kanjinti, a biosimilar to trastuzumab

Trastuzumab Kanjinti

It is estimated that 15% to 20% of women with newly diagnosed breast cancer have tumours that over-express human epidermal growth factor receptor 2 (HER2). These tumours tend to be more aggressive and are associated with poorer outcomes compared to other subtypes. Assuringly, the advent of targeted anti-HER2 . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: